Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

PubWeight™: 1.06‹?› | Rank: Top 15%

🔗 View Article (PMC 3272122)

Published in Semin Immunopathol on December 11, 2011

Authors

Steven Y C Tong1, Luke F Chen, Vance G Fowler

Author Affiliations

1: Division of Infectious Diseases and International Health, Duke University Medical Center, Box 102359, Durham, NC 27705, USA. steven.tong@menzies.edu.au

Associated clinical trials:

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial | NCT01011335

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA) (ZEPHYR) | NCT00084266

Articles citing this

Signaling via the IL-20 receptor inhibits cutaneous production of IL-1β and IL-17A to promote infection with methicillin-resistant Staphylococcus aureus. Nat Immunol (2013) 2.55

Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci (2012) 1.91

Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus promotes host defense with minimal impact on resistance. PLoS Pathog (2014) 1.39

A zebrafish high throughput screening system used for Staphylococcus epidermidis infection marker discovery. BMC Genomics (2013) 1.11

Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother (2012) 1.08

Host- and microbe determinants that may influence the success of S. aureus colonization. Front Cell Infect Microbiol (2012) 1.03

Targeting agr- and agr-Like quorum sensing systems for development of common therapeutics to treat multiple gram-positive bacterial infections. Sensors (Basel) (2013) 1.01

Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother (2012) 0.96

Nox2 modification of LDL is essential for optimal apolipoprotein B-mediated control of agr type III Staphylococcus aureus quorum-sensing. PLoS Pathog (2013) 0.96

Staphylococcal superantigens interact with multiple host receptors to cause serious diseases. Immunol Res (2014) 0.95

The function of TLR2 during staphylococcal diseases. Front Cell Infect Microbiol (2013) 0.92

Identification of the Staphylococcus aureus vfrAB operon, a novel virulence factor regulatory locus. Infect Immun (2014) 0.91

ω-Hydroxyemodin limits staphylococcus aureus quorum sensing-mediated pathogenesis and inflammation. Antimicrob Agents Chemother (2015) 0.85

Colonisation and interaction between S. epidermidis and S. aureus in the nose and throat of healthy adolescents. Eur J Clin Microbiol Infect Dis (2014) 0.83

Modulation of Bacterial Multidrug Resistance Efflux Pumps of the Major Facilitator Superfamily. Int J Bacteriol (2015) 0.83

Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010. Eur J Clin Microbiol Infect Dis (2013) 0.80

Evidence for steric regulation of fibrinogen binding to Staphylococcus aureus fibronectin-binding protein A (FnBPA). J Biol Chem (2014) 0.79

Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL. PLoS One (2016) 0.77

Carriage of Staphylococcus aureus by free-living wild animals in Spain. Appl Environ Microbiol (2014) 0.76

A Systems Biology Approach to the Coordination of Defensive and Offensive Molecular Mechanisms in the Innate and Adaptive Host-Pathogen Interaction Networks. PLoS One (2016) 0.76

Population-based epidemiology of Staphylococcus aureus bloodstream infection: clonal complex 30 genotype is associated with mortality. Eur J Clin Microbiol Infect Dis (2016) 0.76

Phytochemical Composition and Antibacterial Activity of Hydroalcoholic Extracts of Pterospartum tridentatum and Mentha pulegium against Staphylococcus aureus Isolates. Biomed Res Int (2016) 0.75

Octameric structure of Staphylococcus aureus enolase in complex with phosphoenolpyruvate. Acta Crystallogr D Biol Crystallogr (2015) 0.75

Staphylococcal enterotoxin-like X (SElX) is a unique superantigen with functional features of two major families of staphylococcal virulence factors. PLoS Pathog (2017) 0.75

Articles cited by this

(truncated to the top 100)

Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol (2000) 34.08

Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA (2007) 26.98

Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis (1999) 19.52

eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol (2004) 17.92

Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol (2003) 16.45

Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med (2001) 14.84

Evolution of MRSA during hospital transmission and intercontinental spread. Science (2010) 13.34

Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med (2005) 12.75

Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J Clin Microbiol (1999) 11.77

Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol (2009) 10.42

Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet (2002) 10.26

Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med (2010) 8.50

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med (2006) 8.20

Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis (2006) 8.17

Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med (2007) 7.75

Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA (2008) 7.60

Staphylococcal leucocidins. Br J Exp Pathol (1957) 7.42

Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA (2005) 7.41

Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med (2011) 7.07

Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science (2007) 7.06

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis (2011) 6.71

Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep (1999) 6.57

A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med (2005) 6.14

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13

Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med (2007) 5.95

Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med (2008) 5.92

Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med (2011) 5.64

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 5.64

Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet (2004) 5.27

Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med (2008) 5.13

Health care-associated invasive MRSA infections, 2005-2008. JAMA (2010) 4.79

Infections caused by a particular phage type of Staphylococcus aureus. Med J Aust (1955) 4.39

Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc Natl Acad Sci U S A (2008) 4.38

Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis (2010) 4.19

Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis (2008) 4.16

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis (2004) 4.05

A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med (2006) 4.00

Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis (2005) 3.91

Retracted A link between virulence and ecological abundance in natural populations of Staphylococcus aureus. Science (2001) 3.44

Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med (2005) 3.36

Methicillin-resistant Staphylococcus aureus infections in correctional facilities---Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep (2003) 3.35

Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis (2007) 3.31

A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis (2004) 3.29

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis (2011) 3.20

Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog (2010) 3.11

Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA (2009) 3.06

Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A (2010) 3.05

Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med (1971) 2.98

A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science (2008) 2.96

Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med (2005) 2.91

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med (2002) 2.90

Natural population dynamics and expansion of pathogenic clones of Staphylococcus aureus. J Clin Invest (2004) 2.86

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis (2008) 2.73

Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis (1995) 2.69

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother (2005) 2.66

A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis (2008) 2.35

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis (2005) 2.34

Poor functional status as a risk factor for surgical site infection due to methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol (2008) 2.33

Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in indigenous Northern Australia: epidemiology and outcomes. J Infect Dis (2009) 2.20

Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep (2007) 2.20

Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother (2003) 2.20

Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol (2011) 2.20

Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J Infect Dis (2011) 2.19

Diversity among community isolates of methicillin-resistant Staphylococcus aureus in Australia. J Clin Microbiol (2004) 2.17

Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust (2009) 2.16

Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence (2011) 2.14

Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother (2002) 2.12

A point mutation in the agr locus rather than expression of the Panton-Valentine leukocidin caused previously reported phenotypes in Staphylococcus aureus pneumonia and gene regulation. J Infect Dis (2009) 2.12

Infection by penicillin-resistant staphylococci. Lancet (1948) 2.08

Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections. Clin Microbiol Infect (2009) 2.04

Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol (1999) 2.04

Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis (2010) 2.02

Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J Infect Dis (2007) 2.00

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis (2010) 1.92

Curbing methicillin-resistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional control program. Arch Intern Med (2010) 1.91

Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol (2007) 1.91

Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics. PLoS One (2010) 1.89

Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr (2007) 1.89

Understanding the rise of the superbug: investigation of the evolution and genomic variation of Staphylococcus aureus. Funct Integr Genomics (2006) 1.86

Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother (2007) 1.84

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis (2010) 1.78

Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest (2010) 1.76

Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog (2010) 1.74

Methicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med J Aust (2006) 1.73

Sustained reduction in methicillin-resistant Staphylococcus aureus wound infections after cardiothoracic surgery. Arch Intern Med (2010) 1.70

Leukocidal toxins of staphylococci. Zentralbl Bakteriol (1999) 1.68

Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med (1990) 1.67

Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance. FEMS Microbiol Rev (2011) 1.66

Pediatric bone and joint infections caused by Panton-Valentine leukocidin-positive Staphylococcus aureus. Pediatr Infect Dis J (2007) 1.64

Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J Clin Microbiol (2009) 1.64

Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiol Infect (1995) 1.63

Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother (1998) 1.63

Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies. Lancet Infect Dis (2006) 1.60

Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J Infect Dis (2011) 1.59

The environment as an unrecognized reservoir for community-associated methicillin resistant Staphylococcus aureus USA300: a case-control study. PLoS One (2011) 1.57

A play in four acts: Staphylococcus aureus abscess formation. Trends Microbiol (2011) 1.53

Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med (2005) 1.51

A very early-branching Staphylococcus aureus lineage lacking the carotenoid pigment staphyloxanthin. Genome Biol Evol (2011) 1.51

Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci U S A (2010) 1.49

A history of Panton-Valentine leukocidin (PVL)-associated infection protects against death in PVL-associated pneumonia. Vaccine (2011) 1.48

Articles by these authors

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation (2005) 10.98

Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med (2009) 7.82

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis (2003) 4.06

In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med (2013) 3.72

Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis (2006) 3.70

The network approach for prevention of healthcare-associated infections: long-term effect of participation in the Duke Infection Control Outreach Network. Infect Control Hosp Epidemiol (2011) 3.24

Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA (2007) 3.03

Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. JAMA (2012) 3.01

Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J (2004) 2.85

Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation (2015) 2.84

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis (2008) 2.73

Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol (2011) 2.71

Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med (2002) 2.68

Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia. Clin Infect Dis (2011) 2.62

Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis (2013) 2.44

Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis (2005) 2.36

Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother (2005) 2.34

Poor functional status as a risk factor for surgical site infection due to methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol (2008) 2.33

Early predictors of in-hospital death in infective endocarditis. Circulation (2004) 2.26

An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23

Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation (2010) 2.01

Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? Pediatrics (2006) 1.98

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis (2005) 1.95

Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol (2007) 1.91

Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. Am Heart J (2004) 1.90

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother (2006) 1.84

Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis (2009) 1.80

Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis (2004) 1.80

Current definitions of central line-associated bloodstream infection: is the emperor wearing clothes? Infect Control Hosp Epidemiol (2010) 1.79

Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis (2007) 1.78

Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med (2009) 1.76

Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis (2004) 1.73

Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography. Eur J Echocardiogr (2011) 1.72

Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremia. Crit Care Med (2008) 1.69

Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol (2005) 1.69

Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol (2014) 1.67

Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J Clin Microbiol (2009) 1.64

Multiplex PCR to diagnose bloodstream infections in patients admitted from the emergency department with sepsis. J Clin Microbiol (2009) 1.63

Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest (2003) 1.62

Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis (2009) 1.62

Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J Infect Dis (2011) 1.59

Identifying and aligning expectations in a mentoring relationship. Clin Transl Sci (2011) 1.58

Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med (2007) 1.56

Disease progression in hemodynamically stable patients presenting to the emergency department with sepsis. Acad Emerg Med (2010) 1.54

No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants. Pediatr Infect Dis J (2015) 1.53

Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. J Infect (2009) 1.51

Critical role of NOD2 in regulating the immune response to Staphylococcus aureus. Infect Immun (2009) 1.49

[Staphylococcus aureus infections: new challenges from an old pathogen]. Enferm Infecc Microbiol Clin (2006) 1.46

Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet? J Infect Dis (2011) 1.41

Empirical antimicrobial therapy for bloodstream infection due to methicillin-resistant Staphylococcus aureus: no better than a coin toss. Infect Control Hosp Epidemiol (2009) 1.38

Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol (2005) 1.38

Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J Infect Dis (2009) 1.37

Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin Infect Dis (2008) 1.37

Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. J Clin Microbiol (2008) 1.36

Clinical characteristics and outcome of aortic endocarditis with periannular abscess in the International Collaboration on Endocarditis Merged Database. Am J Cardiol (2005) 1.36

Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother (2009) 1.35

Seasonal variation in Klebsiella pneumoniae bloodstream infection on 4 continents. J Infect Dis (2008) 1.35

Staphylococcus aureus bacteraemia in a tropical setting: patient outcome and impact of antibiotic resistance. PLoS One (2009) 1.32

Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PLoS One (2009) 1.28

Discriminative value of inflammatory biomarkers for suspected sepsis. J Emerg Med (2011) 1.26

Staphylococcus aureus bacteremia and endocarditis. Cardiol Clin (2003) 1.26

Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis (2008) 1.26

The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J (2007) 1.26

Repeat infective endocarditis: differentiating relapse from reinfection. Clin Infect Dis (2005) 1.26

High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. Antimicrob Agents Chemother (2013) 1.24

The effect of surgical site infection on older operative patients. J Am Geriatr Soc (2009) 1.24

Staphylococcus aureus bacteremia and endocarditis. Infect Dis Clin North Am (2002) 1.24

Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes. Am J Med (2005) 1.23

Coagulase-negative staphylococcal infections in the neonatal intensive care unit. Infect Control Hosp Epidemiol (2011) 1.19

Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremia. Am J Med (2005) 1.18

Two genes on A/J chromosome 18 are associated with susceptibility to Staphylococcus aureus infection by combined microarray and QTL analyses. PLoS Pathog (2010) 1.17

Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates. Antimicrob Agents Chemother (2010) 1.13

Periannular complications in infective endocarditis involving prosthetic aortic valves. Am J Cardiol (2006) 1.11

Use of surgery in patients with native valve infective endocarditis: results from the International Collaboration on Endocarditis Merged Database. Am Heart J (2005) 1.11

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2006) 1.10

Polymorphisms in fibronectin binding protein A of Staphylococcus aureus are associated with infection of cardiovascular devices. Proc Natl Acad Sci U S A (2011) 1.08

Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients. Clin J Am Soc Nephrol (2008) 1.08

A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect (2004) 1.08

Increasing rates of methicillin-resistant Staphylococcus aureus in academic hospitals: a result of active surveillance? Infect Control Hosp Epidemiol (2013) 1.06

Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia. Pediatrics (2004) 1.05

Antibacterial resistance leadership group: open for business. Clin Infect Dis (2014) 1.04

Osteoblasts express the inflammatory cytokine interleukin-6 in a murine model of Staphylococcus aureus osteomyelitis and infected human bone tissue. Am J Pathol (2004) 1.04

Presence of genes encoding panton-valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus. J Clin Microbiol (2012) 1.04

Complex surgical site infections and the devilish details of risk adjustment: important implications for public reporting. Infect Control Hosp Epidemiol (2008) 1.02

Osteoblasts produce monocyte chemoattractant protein-1 in a murine model of Staphylococcus aureus osteomyelitis and infected human bone tissue. Bone (2005) 1.02

Using decision analysis to improve malaria control policy making. Health Policy (2009) 1.00

Potential associations between severity of infection and the presence of virulence-associated genes in clinical strains of Staphylococcus aureus. PLoS One (2011) 0.99

Incidence of and preoperative risk factors for Staphylococcus aureus bacteremia and chest wound infection after cardiac surgery. Infect Control Hosp Epidemiol (2009) 0.99

Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient Staphylococcus aureus strains. J Med Microbiol (2003) 0.99

Periannular complications in infective endocarditis involving native aortic valves. Am J Cardiol (2006) 0.99

Gene expression-based classifiers identify Staphylococcus aureus infection in mice and humans. PLoS One (2013) 0.99

Influence of diabetes mellitus on the clinical manifestations and prognosis of infective endocarditis: a report from the International Collaboration on Endocarditis-Merged Database. Scand J Infect Dis (2006) 0.98

Correlation between fundamental binding forces and clinical prognosis of Staphylococcus aureus infections of medical implants. Langmuir (2007) 0.98

Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2008) 0.98

Transmission of MRSA between companion animals and infected human patients presenting to outpatient medical care facilities. PLoS One (2011) 0.98

Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2007) 0.98

Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI Summit. Clin Infect Dis (2008) 0.97

Candida endocarditis: contemporary cases from the International Collaboration of Infectious Endocarditis Merged Database (ICE-mD). Scand J Infect Dis (2004) 0.97

The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort. Am Heart J (2005) 0.96